|
1
|
de Lima MC, de Castro CC, Aguiar KEC, Monte N, da Costa Nunes GG, da Costa ACA, Rodrigues JCG, Guerreiro JF, Ribeiro-dos-Santos Â, de Assumpção PP, Burbano RMR, Fernandes MR, dos Santos SEB, dos Santos NPC. Molecular Profile of Important Genes for Radiogenomics in the Amazon Indigenous Population. J Pers Med 2024; 14:484. [PMID: 38793065 PMCID: PMC11122349 DOI: 10.3390/jpm14050484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Revised: 04/13/2024] [Accepted: 04/18/2024] [Indexed: 05/26/2024] Open
Abstract
Radiotherapy is focused on the tumor but also reaches healthy tissues, causing toxicities that are possibly related to genomic factors. In this context, radiogenomics can help reduce the toxicity, increase the effectiveness of radiotherapy, and personalize treatment. It is important to consider the genomic profiles of populations not yet studied in radiogenomics, such as the indigenous Amazonian population. Thus, our objective was to analyze important genes for radiogenomics, such as ATM, TGFB1, RAD51, AREG, XRCC4, CDK1, MEG3, PRKCE, TANC1, and KDR, in indigenous people and draw a radiogenomic profile of this population. The NextSeq 500® platform was used for sequencing reactions; for differences in the allelic frequency between populations, Fisher's Exact Test was used. We identified 39 variants, 2 of which were high impact: 1 in KDR (rs41452948) and another in XRCC4 (rs1805377). We found four modifying variants not yet described in the literature in PRKCE. We did not find any variants in TANC1-an important gene for personalized medicine in radiotherapy-that were associated with toxicities in previous cohorts, configuring a protective factor for indigenous people. We identified four SNVs (rs664143, rs1801516, rs1870377, rs1800470) that were associated with toxicity in previous studies. Knowing the radiogenomic profile of indigenous people can help personalize their radiotherapy.
Collapse
Affiliation(s)
- Milena Cardoso de Lima
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Cinthia Costa de Castro
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Kaio Evandro Cardoso Aguiar
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Natasha Monte
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Giovanna Gilioli da Costa Nunes
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Ana Caroline Alves da Costa
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Juliana Carla Gomes Rodrigues
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - João Farias Guerreiro
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
- Laboratory of Human and Medical Genetics, Federal University of Pará, Belém 66075-110, PA, Brazil;
| | | | - Paulo Pimentel de Assumpção
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Rommel Mario Rodríguez Burbano
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Marianne Rodrigues Fernandes
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| | - Sidney Emanuel Batista dos Santos
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
- Laboratory of Human and Medical Genetics, Federal University of Pará, Belém 66075-110, PA, Brazil;
| | - Ney Pereira Carneiro dos Santos
- Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil; (M.C.d.L.); (C.C.d.C.); (K.E.C.A.); (N.M.); (G.G.d.C.N.); (A.C.A.d.C.); (J.C.G.R.); (J.F.G.); (P.P.d.A.); (R.M.R.B.); (M.R.F.)
| |
Collapse
|
|
2
|
Balma M, Liberini V, Racca M, Laudicella R, Bauckneht M, Buschiazzo A, Nicolotti DG, Peano S, Bianchi A, Albano G, Quartuccio N, Abgral R, Morbelli SD, D'Alessandria C, Terreno E, Huellner MW, Papaleo A, Deandreis D. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. Front Med (Lausanne) 2022; 9:881551. [PMID: 35492341 PMCID: PMC9039137 DOI: 10.3389/fmed.2022.881551] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 03/22/2022] [Indexed: 02/05/2023] Open
Abstract
Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.
Collapse
Affiliation(s)
- Michele Balma
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- *Correspondence: Michele Balma
| | - Virginia Liberini
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Division of Nuclear Medicine, Department of Medical Science, University of Turin, Turin, Italy
| | - Manuela Racca
- Nuclear Medicine Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| | - Riccardo Laudicella
- Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy
- Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Nuclear Medicine Unit, Fondazione Istituto G. Giglio, Cefalù, Italy
| | - Matteo Bauckneht
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
| | - Ambra Buschiazzo
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
| | | | - Simona Peano
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
| | - Andrea Bianchi
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
| | - Giovanni Albano
- Nuclear Medicine Unit, Fondazione Istituto G. Giglio, Cefalù, Italy
| | - Natale Quartuccio
- Nuclear Medicine Unit, A.R.N.A.S. Civico di Cristina and Benfratelli Hospitals, Palermo, Italy
| | - Ronan Abgral
- Department of Nuclear Medicine, University Hospital of Brest, Brest, France
| | - Silvia Daniela Morbelli
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
| | | | - Enzo Terreno
- Department of Molecular Biotechnology and Health Sciences, Molecular & Preclinical Imaging Centers, University of Turin, Turin, Italy
| | - Martin William Huellner
- Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Alberto Papaleo
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
| | - Désirée Deandreis
- Division of Nuclear Medicine, Department of Medical Science, University of Turin, Turin, Italy
| |
Collapse
|
|
3
|
Yang J, Jia C, Yang J. Designing Nanoparticle-based Drug Delivery Systems for Precision Medicine. Int J Med Sci 2021; 18:2943-2949. [PMID: 34220321 PMCID: PMC8241788 DOI: 10.7150/ijms.60874] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 05/25/2021] [Indexed: 02/05/2023] Open
Abstract
Traditional drugs are facing bottlenecks of lower solubility, absorption, and especially the inefficient organs or cells targeting during the precision medicine era. It is urgently needed to discover and establish new methods or strategies to modify old drugs or create new ones against the above defects. With the support of nanotechnology, the solubility, absorption and targeting of traditional drugs were greatly improved by modifying and fabricating with various types of nanoparticles to some extent, though many shortages remain. In this mini-review we will focus on advances in several most commonly used nanoparticles, from their nature and design, to drug delivery system and clinical application, that they overcome heterogeneous barriers in precision medicine, thereby ultimately improve patient outcome overall.
Collapse
Affiliation(s)
- Jianhua Yang
- Department of Orthopaedics, Longgang District People's Hospital, Shenzhen 518172, China
| | - Chengyou Jia
- Shanghai Research Center for Thyroid Diseases, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
| | - Jianshe Yang
- Shanghai Research Center for Thyroid Diseases, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.,Health and Life Science College, the Chinese University of Hong Kong, Shenzhen 518172, China
| |
Collapse
|